Objective: The impact of GCA and its treatment on an individual’s life is poorly characterised. This research sought to advance existing qualitative literature to tailor better diagnostic frameworks, treatment approaches and therapeutic relationships that focus on outcomes that are important to patients. Methods: A qualitative study using phenomenology was undertaken. Purposive sampling selected recently diagnosed participants with varied experiences, including those with and without a confirmatory diagnostic test, vision loss, prednisolone adverse effects and psychosocial impact. Semi-structured interviews were conducted until saturation. Themes emerged through data interpretation, bringing together common experiences and their variant manifestations to elucidate the lived experience of GCA. Results: Of 34 individuals invited, 20 agreed to participate; 12 (60%) were female, median age at diagnosis 68 years (range 58–86) and mean time since diagnosis 15.7 months (range 1–45). Four main themes emerged: living with uncertainty and fear, change in self-perception and loss of autonomy, adapting to physical symptoms and the critical importance of the healthcare interaction. Conclusion: This study provides unique insights into the lived experiences of individuals with recently diagnosed GCA. Our findings emphasise the profound psychological and functional impact of GCA and recognise the critical importance of patient experience on overall well-being. These insights demand we move towards a patient-centred model of care that goes beyond disease control, prioritising clear communication, tailored patient education, support networks and integrated service provision. Addressing these unmet needs represents a critical opportunity to improve outcomes that are important to people living with GCA.
21 September 2026 in Rheumatology Advances in Practice
Objectives: Disadvantageous socioeconomic status (SES) is associated with poorer disease outcomes for people living with rheumatoid arthritis (RA). We aimed to determine how people living with both RA and socioeconomic disadvantage navigate the healthcare system. In particular, we aimed to determine how their SES influences their interactions with the healthcare system and how it modifies the care they receive, influencing health outcomes. Methods: This was a qualitative study utilizing patient journey mapping techniques. In-depth, semi-structured interviews were conducted by two interviewers. Interview transcripts were coded, and reflexive thematic analysis (TA) was undertaken through sequential rounds of theme generation until thematic consensus was achieved. Themes were synthesized and interpreted using the cumulative complexity (CC) model and candidacy framework (CF). Results: Following purposeful sampling, 42 individuals met inclusion criteria, and interviews were ultimately arranged with eight individuals [50% female, median age 58.5 (IQR 56–66.5)]. Interviews lasted mean 88.5 min (SD 13.6). Most participants were unemployed and receiving social benefits. Six key themes were identified: the challenges of acknowledging and attributing symptoms, building health literacy, maintaining effective relationships with healthcare staff, managing treatment challenges, living with trauma and adapting to chronic illness. Conclusion: Individuals with low SES have unique experiences of RA care, influencing all aspects of their RA health journey. Using the CC and CF, the themes identified in this study highlight actionable strategies to improve care pathways to better support individuals living with greater cumulative complexity and disadvantage.
Background: Polymyalgia rheumatica is the commonest inflammatory condition affecting adults over 50 years of age, however it has been under‐researched and management varies in everyday clinical practice. Aim: This national survey of rheumatologists and trainees managing polymyalgia rheumatica (PMR) in Australia sought to determine current diagnostic and management approaches and establish a baseline for future development of a disease‐specific clinical care standard. Methods: Following ethics approval, an online survey was circulated to the membership of the Australian Rheumatology Association. Relevant demographic information about respondents was collected, along with answers to multiple‐choice questions on the clinical presentation, diagnosis, management and prognosis of PMR. Free‐text responses were also permitted at the end of each section. The survey remained open between 25 March 2022 and 11 November 2022. Data analysis involved descriptive statistics for multiple‐choice questions and thematic analysis for free‐text responses. Results: Seventy‐nine clinicians completed the survey, of whom the majority were qualified rheumatologists who regularly managed patients with PMR. Most respondents relied upon clinical diagnosis, but some did not recognise peripheral joint involvement or normal inflammatory markers as possible features of PMR. Access to imaging investigations like 18 F‐fluorodeoxyglucose positron emission tomography combined with computed tomography was limited but desirable in circumstances of diagnostic uncertainty. Management predominantly involved glucocorticoid monotherapy; however, long‐term outcomes were diverse and almost every clinician had prescribed a conventional synthetic DMARD for steroid‐sparing purposes. The use of adjunctive physical therapy was inconsistent. Conclusion: Variability remains in the diagnosis and management of PMR among Australian clinicians, with gaps in recognition of atypical presentations, imaging access and incorporation of physical therapy, ultimately supporting the need for standardised, evidence‐based clinical care guidelines.